IP Library Granted Patent US 9,815,889
Granted Patent B2
US 9,815,889 · App. 14/964,763 · Granted Nov 14, 2017

Antibodies for prevention and treatment of diseases caused by clostridium difficile

Inventors: Peter H. Seeberger (Kleinmachnow, DE); Christopher E. Martin (Berlin, DE); Felix Broecker (Berlin, DE); Chakkumkal Anish (Berlin, DE)
Assignee: Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V.
C07K16/1282A61K31/715A61K39/40C07K16/44A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,815,889
App. No.
14/964,763
Granted
Nov 14, 2017
Kind
B2
Abstract

The present invention relates to an antibody having specificity for an immunogenic determinant consisting of the pentasaccharide repeating unit of the Clostridium difficile glycopolymer PS-I: α- L -Rhap-(1→3)-β- D -Glcp-(1→4)-[α- L -Rhap-(1→3)]-α- D -Glcp-(1→2)-α- D -Glcp or a fragment thereof. Said antibody is able to prevent and treat diseases caused by C. difficile . The present invention further pertains to a method of treating or preventing a disease caused by the pathogen Clostridium difficile , which comprises administering to a subject said antibody or a vaccine composition comprising said antibody.

Claims (4)

1. An antibody having specificity for an immunogenic determinant comprising the pentasaccharide α-L-Rhap-(1→3)-β-D-Glcp-(1→4)-[α-L-Rhap-(1→3)]-α-D-Glcp-(1→2)-α-D-Glcp or a fragment of the pentasaccharide wherein the antibody is the monoclonal antibody 2C5 (accession number DSM ACC3282), 10A1 (accession number DSM ACC3283), or 10D6 (accession number DSM ACC3284).

2. A vaccine composition comprising at least one antibody according to claim 1 and a pharmaceutically acceptable carrier.

3. A method for treatment or prevention of a disease caused by the pathogen Clostridium difficile , which comprises administering to a subject the antibody according to claim 1 .

4. A method for treatment or prevention of a disease caused by the pathogen Clostridium difficile , which comprises administering to a subject the vaccine composition according to claim 2 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 26, 2016
From: SEEBERGER, PETER H.; MARTIN, CHRISTOPHER E.; BROECKER, FELIX; ANISH, CHAKKUMKAL
To: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Reel/Frame 037582/0323 →
Priority Claims (1)
EP 11006355 · Aug 2, 2011 · regional
Continuity (3)
Continuation In Part 14236620
Provisional Application 61514095 · Aug 2, 2011
Related Publication 20160137724A1 · May 19, 2016